US20200018753A1 - Non-invasive biomarker to identify subject at risk of preterm delivery - Google Patents
Non-invasive biomarker to identify subject at risk of preterm delivery Download PDFInfo
- Publication number
- US20200018753A1 US20200018753A1 US16/523,832 US201916523832A US2020018753A1 US 20200018753 A1 US20200018753 A1 US 20200018753A1 US 201916523832 A US201916523832 A US 201916523832A US 2020018753 A1 US2020018753 A1 US 2020018753A1
- Authority
- US
- United States
- Prior art keywords
- pgds
- preterm
- pregnant woman
- inhibitor
- prostaglandin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/99—Isomerases (5.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Definitions
- This invention relates generally to methods for diagnosis of increased risk for preterm delivery during pregnancy.
- the invention also relates to compositions and methods for applications of specific prostaglandin D2 receptor (DP1 and DP2) antagonists as novel tocolytic therapeutic agents.
- the invention relates to applications wherein women with a diagnosis of preterm labor or at significant risk for preterm delivery, based on medical history and/or other factors, might be tested.
- the invention also relates to applications wherein pregnant women generally may be tested at 28 weeks of pregnancy to assess the likelihood of preterm delivery.
- Preterm birth is a leading cause of neonatal morbidity and mortality, accounting for 35% of infant healthcare spending and 10% of all childcare spending in the United States.
- medical costs from birth to one year of age are 10-fold greater for babies born premature and/or at low-birth weight when compared to those for babies born full-term.
- the rate of preterm birth has steadily increased by 20% since 1990, with 12.5% of all U.S. births being preterm births.
- H-PGDS cellular localization of H-PGDS appeared to change with gestational age, and by term, immunoreactive H-PGDS was mainly localized to cells lining the villous capillaries, with little or no labeling observed in the syncytium. Labeling was completely absent in the corresponding negative controls in which primary antibody was preincubated with a 10-fold excess of blocking peptide or was omitted completely.
- strong immunolabeling for L-PGDS was observed in the cells of all tissues, including amnion epithelial, reticular, chorionic trophoblast, and dccidual cells.
- L-PGDS mRNA was detectable in amnion, choriodecidual, and villous placental samples There was no significant effect of preterm intrauterine infection or term labor on the level of expression of L-PGDS mRNA. L-PGDS mRNA levels were significantly higher in the choriodecidua and placenta than in the amnion. There was no significant difference in the level of expression between the choriodecidua and placenta. The expression of H-PGDS mRNA was detectable in all three tissues, with no significant effect of preterm intrauterine infection or labor at term. Analyzing the combined data for each tissue revealed that the relative expression of H-PGDS mRNA was lowest in the amnion and choriodecidua, with a significantly higher level of expression in the villous placenta.
- L-PGDS lipocalin-type prostaglandin D2 synthase
- an L-PGDS concentration level higher than 1.8 ⁇ g/ml indicates an increased likelihood for preterm delivery.
- the cervical vaginal secretion may be collected with a sponge.
- At least one prostaglandin D2 receptor antagonist may be administered as a tocolytic agent.
- the at least one prostaglandin D2 receptor antagonist may comprises a DPI receptor antagonist and/or a DP2 receptor antagonist.
- the L-PGDS concentration level may be determined using an antibody sandwich Enzyme-Linked ImmunoSorbent Assay (ELISA).
- ELISA Enzyme-Linked ImmunoSorbent Assay
- the L-PGDS concentration levels may be normalized to protein levels in the cervical vaginal secretions for analysis.
- the at least one prostaglandin DP1 or prostaglandin DP2 receptor antagonist comprises one or more agents selected from the group consisting of AM156 ( ⁇ 2′-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-6-methoxy-4′-trifluoro-methyl-biphenyl-3-y11-acetic acid, sodium salt), and AM206 ⁇ 2-Rbenzoyloxycarbonyl-ethyl-amino)-methy11-4-trifluoromethyl-phenyll-pyridin-3-yl)-acetic acid, sodium salt), MK-0524 ([(3R)-4-(4-Chloro-benzyl)-7-fluoro-5-(tnethylsulfony1)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yThacetie Acid), AM-853 (2-(4-(4-(tert-butylcarbamoyl)-2
- an L-PGDS inhibitor may be used, for example, AT-56 (4-dibenzo[a,d]cyclohepten-5-ylidene-1-[4-(2H-tetrazol-5-yl)-butyl]-piperidine).
- Resveratrol has been shown to reduce formation of Prostaglandin D2 presumably by inhibiting cyclooxygenase (COX), especially COX-2.
- COX cyclooxygenase
- the at least one prostaglandin DP1 or prostaglandin DP2 receptor antagonist is administered orally, by inhalation, through a mucous membrane, transdermally, topically, rectally, or parenterally.
- a further object provides a pharmaceutical formulation comprising a therapeutic amount of a non-teratogenic comprising at least one prostaglandin DP1 or prostaglandin DP2 receptor antagonist and/or an L-PGDS inhibitor, in an effective amount to delay preterm delivery in a pregnant human when administered in repeated doses.
- FIG. 2 present data from a study of samples of pregnant women correlating L-PGDS levels in cervical vaginal secretions with term or preterm delivery.
- FIG. 4 shows 2D PAGE of Human CVS L-PGDS Isoforms.
- Cervical vaginal secretions arc readily collected and constitute a′ minimally invasive procedure.
- a Week-gel sponge is applied into the cervical os for approximately one minute.
- the sponge is then removed and placed in a buffer solution containing physiological saline, Trizma buffer, protease inhibitors (EDTA, phenylmethylsulfonyl fluoride, pepstatin) and antibacterial agents (such as sodium azide).
- EDTA protease inhibitors
- pepstatin protease inhibitors
- antibacterial agents such as sodium azide
- the buffer solution has a low protein concentration, e.g., is produced with a small amount or no bovine serum albumin (BSA). This BSA is not required to stabilize the L-PGDS, and may interfere with its measurement.
- BSA bovine serum albumin
- L-PGDS concentration levels from the cervical vaginal secretion samples are then determined by an antibody sandwich ELISA.
- antibody against L-PGDS raised in rabbits is purified by hydroxyapatite chromatography, followed by an immunoaffinity purification on an Affi-Gel 15 Gel column.
- the purified antibody is then diluted to 10 ⁇ g/ml in 0.2M sodium carbonate buffer, pH 9.0, and 50 ⁇ l added to each well of an Nunc-Immuno plate with Maxi Sorp surface overnight at 4° C.
- the wells are then washed with 0.1% BSA/0.05% Tween 20 in PBS 4 times and blocked with 1% BSA in PBS for 1 hour.
- Diluted plasmas or L-PGDS standards (1.2 to 75 ng/ml) are incubated in Block for 90 minutes, then washed as above.
- a secondary anti-L-PGDS antibody, raised in chickens, at 4 ng/ml in wash buffer, is incubated in the wells for 1 hour and then washed, as above.
- a key advantage of this assay over the current fetal fibronectin (fFN) test is that the present assay would predict preterm birth over the entire gestational period up to parturition.
- a negative fFN although very accurate, is only valid for a 2-week window.
- the present assay showed elevated L-PGDS, and was predictive for preterm birth.
- FIG. 2 shows results from a larger study.
- Table 3 shows data demonstrating that in LPS-induced preterm birth, there is a three-fold increase in viable mouse pups/pregnancy in the L-PGDS knockouts and a 15-fold decrease in viable pups/pregnancy in the L-PGDS transgenic overexpressors when compared to the C57BL/6 controls. This implies that L-PGDS is casually related to preterm birth, and not merely correlated with it.
- prostaglandin D2 receptor antagonists may be administered to pregnant mammals to interrupt preterm labor, and more particularly, to avoid preterm labor induced by infectious agents, especially those which produce lipopolysaccharides. Because the preterm labor pathway has common elements, it is likely that the prostaglandin D2 receptor antagonists will also act to block preterm labor from other causes.
- available prostaglandin D2 (DP1/DPGTR, DP2/CRTH2) receptor antagonists include AM156 (12′-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-6-methoxy-4′-trifluoro-methyl-biphenyl-3-yl ⁇ -acetic acid, sodium salt), and AM206 (5- ⁇ 2-[(benzoyloxycarbonyl-ethyl-amino)-methyl]-4-trifluoromethyl-phenyl-pyridin-3-yl)-acetic acid, sodium salt), MK-0524 ([(3R)-4-(4-Chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indo1-3-yl]-acetic Acid), AM-853 (2-(4-(4-(tert-butylcarbamoyl)-2-(2-chloro-4-cyclopropy
- the tocolytic therapeutic agents may be administered orally, by inhalation spray, topically, transdermally, parenterally or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
- parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
- Tocolytic therapeutic agents e.g., prostaglandin D2 receptor antagonists, may be co-administered with other therapeutic agents and are suitable for simultaneous and/or sequential combination therapies.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 15/708,582, filed Sep. 19, 2017, now U.S. Pat. No. ______; which is a continuation of U.S. patent application Ser. No. 14/438,110, filed Apr. 23, 2015, now U.S. Pat. No. 9,797,903; which is a 371 national phase of International Application No. PCT/US2013/066490, filed Oct. 24, 2013; which claims the benefit of U.S. Provisional Patent Application 61/717,724, filed Oct. 24, 2012; the contents of which are incorporated herein by reference in their entirety.
- This invention relates generally to methods for diagnosis of increased risk for preterm delivery during pregnancy. The invention also relates to compositions and methods for applications of specific prostaglandin D2 receptor (DP1 and DP2) antagonists as novel tocolytic therapeutic agents. The invention relates to applications wherein women with a diagnosis of preterm labor or at significant risk for preterm delivery, based on medical history and/or other factors, might be tested. The invention also relates to applications wherein pregnant women generally may be tested at 28 weeks of pregnancy to assess the likelihood of preterm delivery.
- Preterm birth is a leading cause of neonatal morbidity and mortality, accounting for 35% of infant healthcare spending and 10% of all childcare spending in the United States. In addition, medical costs from birth to one year of age are 10-fold greater for babies born premature and/or at low-birth weight when compared to those for babies born full-term. The rate of preterm birth has steadily increased by 20% since 1990, with 12.5% of all U.S. births being preterm births. Thus, there is a clear and significant need to understand the biological and molecular mechanisms leading to preterm birth, as well as to improve a physician's ability to predict which women are at risk for preterm delivery.
- There are approximately 500,000 preterm in births per year in the United States, of which approximately 30-70% are associated with an underlying infectious process. Infection is a major risk factor for pre-term birth after the most consistently identified risks factors, which include: a history of preterm birth, current multi-fetal pregnancy, and some uterine and/or cervical abnormalities. The ability to identify high-risk pregnancies at an early stage will lead to a significant reduction in the incidence of preterm birth and most likely reduce the incidence of fetal demise, decrease the rate of cerebral palsy, and other neuro-developmental delays. By improving our ability to identify those at risk of preterm birth, we also provide for the development of new and more effective treatments for preterm labor.
- There is little overlap between the current biomarkers of preterm birth, suggesting that these various biomarkers predict different pathways that lead to preterm birth, and suggesting that the creation of a highly predictive biomarker would be beneficial. Currently, there are a handful of biomarkers which attempt to predict preterm labor in advance in order to prevent preterm delivery. These biomarkers include fetal fibronectin, salivary estriol, decidual proteins, and endocrinelparacrine. Fetal fibronectin and salivary estriol have been examined in some detail, with fetal fibronectin now being made available commercially. The fetal fibronectin test is based on the detection of fetal fibronectin, a fetal-specific glycosylated form of fibronectin. The theory is that increased amounts of fetal fibronectin signal the disturbance of the junction of the fetal membranes and the placental deciduas and therefore predicts delivery. In symptomatic pregnant women, the test has only limited effectiveness (58% sensitivity) to predict preterm delivery before the completion of 37 weeks gestation. The main benefit of the present test is the ability to exclude the possibility of preterm delivery (85% specificity) and to avoid unnecessary interventions. Parturition is comprised of 5 events: (1) membrane rupture; (2) cervical dilation; (3) myometrial contaction; (4) placental separation; and (5) uterine involution. While previously available tests might focus on detection of only a subset of these five events (and thus potentially lead to a heightened likelihood for “false positives” in the detection of a purported increased likelihood of preterm birth conditions), the present invention relates to a novel method for heightened sensitivity (e.g., detection of a unified factor relating to all 5 significant steps in parturition), coupled with a more practical effectiveness to diagnosis and possibly treat or prevent a broader range of potential preterm birth conditions. See, U.S. Pat. Nos. 4,919,889; 5,096,830; 5,223,440; 5,281,522; 5,431,171; 5,468,619; 5,516,702; 5,597,700; 5,641,636; 5,650,394; 5,698,404; 5,783,396; 5,877,029; 5,891,722; 5,968,758; 6,126,597; 6,126,616; 6,140,099; 6,149,590; 6,267,722; 6,312,393; 6,394,952; 6,544,193; 6,556,977; 6,610,480; 6,678,669; 6,867,051; 6,875,567; 6,936,476; 7,041,063; 7,191,068; 7,228,295; 7,270,970; 7,403,805; 7,488,585; 7,524,636; 7,528,133; 7,654,957; 7,709,272; 7,756,559; 7,809,417; 7,811,279; 7,863,007; 7,943,294; 8,060,195; 8,068,990; 8,114,610; 8,133,859; 8,160,692; 8,366,640; 8,372,581; 8,501,688; 8,517,960; 8,552,364; U.S. Pat. Pub. Nos. 20010023419; 20010025140; 20010053876; 20020031513; 20020046054; 20020049389; 20030004906; 20030099651; 20030105731; 20030113319; 20030139687; 20040014063; 20040039297; 20040039298; 20040078219; 20040100376; 20040197930; 20040241752; 20040266025; 20050101841; 20050131287; 20050163771; 20050260683; 20050277912; 20060008923; 20060014302; 20060024722; 20060024723; 20060024724; 20060024725; 20060024757; 20060040337; 20060166242; 20060166295; 20060204532; 20060240495; 20060240498; 20070016074; 20070128589; 20070142718; 20070161125; 20080009552; 20080090759; 20080254479; 20080299594; 20090036761; 20090055099; 20090058072; 20090068692; 20090081206; 20090171234; 20090227036; 20090299212; 20100008911; 20100017143; 20100029006; 20100093621; 20100145180; 20100311190; 20100318025; 20110028807; 20110040161; 20110065139; 20110090048; 20110159533; 20110166070; 20110184254; 20110237972; 20110312927; 20110312928; 20120009609; 20120040356; 20120046261; 20120052595; 20120082598; 20120157422; 20120196285; 20120202740; 20120238469; 20120238894; 20120270747; 20130029957; 20130053670; 20130071865 20130171672; 20130177485; and 20130225922, each of which is expressly incorporated herein by reference.
- Measurement of changes in Lipocalin-type prostaglandin D2 synthase (L-PGDS) levels in human cervicovaginal fluid has been suggested as a possible indicator of membrane rupture during pregnancy. Shiki Y, Shimoya K, Tokugawa Y, Kimura T, Koyama M, Azuma C, Murata Y, Eguchi N, Oda H, Urade Y 2004 Changes of lipocalin-type prostaglandin D synthase level during pregnancy. J Obstet Gynaecol Res 30:65-70 (37), each of which is expressly incorporated herein by reference.
- Rachel J. A. Helliwell, Jeffrey A. Keelan, Keith W. Marvin, Linda Adams, Maxwell C. Chang, Ashmit Anand, Timothy A. Sato, Simon O'Carroll, Tinnakom Chaiworapongsa, Roberto J. Romero, and Murray D. Mitchell, “Gestational Age-Dependent Up-Regulation of Prostaglandin D Synthase (PGDS) and Production of PGDS-Derived Antiinflammatory Prostaglandins in Human Placenta”, The Journal of Clinical Endocrinology & Metabolism, vol. 91 no. 2 pp. 597-606 (Feb. 1, 2006), each of which is expressly incorporated by reference, discuss that The two isoforms of PGDS (L-PGDS and H-PGDS) immunolocalized to distinct regions of human term and preteen gestational tissues. In placental villous tissues, specific labeling for L-PGDS was identified in the syncytiotrophoblast layer of both preterm and term placenta, with prominent staining of the apical membrane. At term, cytoplasmic syncytial staining was readily apparent in the syncytium, giving rise to a characteristic beaded appearance. Similarly, strong H-PGDS immunolabeling was observed in the syncytial layer of the preterit” placenta. However, cellular localization of H-PGDS appeared to change with gestational age, and by term, immunoreactive H-PGDS was mainly localized to cells lining the villous capillaries, with little or no labeling observed in the syncytium. Labeling was completely absent in the corresponding negative controls in which primary antibody was preincubated with a 10-fold excess of blocking peptide or was omitted completely. In gestational membranes collected from both preterm and term pregnancies, strong immunolabeling for L-PGDS was observed in the cells of all tissues, including amnion epithelial, reticular, chorionic trophoblast, and dccidual cells. In contrast, only very weak labeling of the gestational membranes was observed for H-PGDS. No labeling was observed in the corresponding negative controls. No significant staining of infiltrating leukocytes was apparent, although on some slides occasional cells positive for L- or H-PGDS were visualized among maternal blood cells. There was no statistical difference in the net amount of H-PGDS in any tissue as a result of the onset of labor at term or the presence of intrauterine infection preterm. Immunoreactive L-PGDS was undetectable in gestational tissues. L-PGDS mRNA was detectable in amnion, choriodecidual, and villous placental samples There was no significant effect of preterm intrauterine infection or term labor on the level of expression of L-PGDS mRNA. L-PGDS mRNA levels were significantly higher in the choriodecidua and placenta than in the amnion. There was no significant difference in the level of expression between the choriodecidua and placenta. The expression of H-PGDS mRNA was detectable in all three tissues, with no significant effect of preterm intrauterine infection or labor at term. Analyzing the combined data for each tissue revealed that the relative expression of H-PGDS mRNA was lowest in the amnion and choriodecidua, with a significantly higher level of expression in the villous placenta.
- See also, Olson D M, Ammann C, “Role of the prostaglandins in labour and prostaglandin receptor inhibitors in the prevention of preterm labour”, Front Biosci.; 12:1329-43 (Jan. 1, 2007)., and Pirianov G, Waddington S N, Lindstrom T M, Terzidou V, Mehmet H, Bennett P R, “The cyclopentenone 15-deoxy-delta12,14-prostaglandin J2 delays lipopolysaccharide-induced preterm delivery and reduces mortality in the newborn mouse”, Endocrinology 150(2):699-706 (Epub 2008 October 9, February 20909), each of which is expressly incorporated herein by reference.
- U.S. Pat. No. 7,399,596 and US 20070020609, expressly incorporated herein by reference, discusses using L-PGDS levels to predict pregnancy-induced hypertension. See also, U.S. Pat. Nos. 7,902,373, 7,794,953, 7,582,643, 7,314,727, 7,109,044, 6,790,635, 6,605,705, 6,410,583, 20110021599, 20100323911, 20100251394, 20080233597, 20080227113, 20070196864, 20070003992, 20040038314, 20030190678, each of which is expressly incorporated herein by reference.
- Specific DP1/DP2 agonists and antagonists are available, e.g., BW245C (5-(6-carboxyhexyl)-1-(3-cyclohexy1-3-hydroxypropyl-hydantoin), AS702224, TS-022, 15R-methyl-PGD2, 13-14-dihydro-15-keto-PGD2, AM156, AM206, L-745870, 15R-PGD(2), MK-0524, BWA868C, BW24-SC, BAY-u3405, 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2), 11-deoxy-11-methylene PGD2, G06983 (PKCα,Δ,ϵ,ζ, G06976 (PKCα), GF10923X (PKCα,Δ,ϵ), LY333531 (PKC β), SB203580 (p38MAPK), SB203580, CD200, FGF18, GPRCSD, GPR49, LRRC15, Serpin A, CDT6, BMP2, LHX2, THBS1, MYCN, NR4A2, MEST, TM4SF1, CRLF1, TNFRSF12A, SELENBP1, GPR161, HEPH, FZD7, and CLIC4, CCL18, Col11A1, Col11Al, CD4, Cdla, FCER1A, HLA-C, HLA-DPA1, IGF I, GPR105, PDGFRL, ADRA2A, CCL19, CORN, 16-phenoxy-17,18,19,20-tetranor PGD2 N-cyclopropylamide, 16-phenoxy-1718,19,20-tctranor PGD1 N-cyclopropylmethylamide, 16-phenoxy-17,18,19,20-PGD1N-(1,3-dihydroxypropan-2-yl))amide; 17-phenyl-18,19,20-trinor PGD2 N-cyclopropylamide, 17-phenyl-18,19,20-trinor PGD1N-cyclopropylmethylamide, 17-phenyl-18,19,20-trinor PGD2N-(1,3-dihydroxypropan-2-yl))amide; 16-(3-chloropheny1)-17,18,19,20-tetranor PGD2 N-cyclopropylamide, 16-(3-chloropheny0-17,18,19,20-tetranor PGD1N-cyclopropylmethylamide, 6-(3-chloropheny1)-17,18,19,20-tetranor PGD1 N-(1,3-dihydroxypropan-2-yl))amide, (Z)-isopropyl 7-((R)-2-((R)-3-hydroxy-5-phenylpentyl)-5-oxocyclopent-2-enyphept-5-enoate, (Z)-isopropyl 7-((R)-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy) but-l-eny1)-5-oxo-cyclopent-2-enyl)hept-5-enoate, (Z)-N-ethyl-7-((R)-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-l-eny1)-5-oxocyclopent-2-enyl)hept-5-enamide, (Z)-N-ethyl-7-((R)-2-((S,E)-3-hydroxy-5-phenylpent-1-eny1)-5-oxocyclopen-t-2-enyl) hept-5-enamide, (Z)-7-((R)-2-((R,E)-3-hydroxy-4-(3-(tritluoromethyl)phenoxy)but-l-eny1)-5-oxocyclopent-2-enyl)hept-5-enoic acid, (Z)-7-((R)-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl) phenoxy)but-l-eny1)-5-oxocyclopent-2-enyl)-N-methylhept-5-enamide, (Z)-7-((R)-2-((R,E)-4-(3-chlorophenoxy)-3-hydroxybut-1-eny1)-5-oxocyclope-nt-2-enyl)hept-5-enoic acid, (Z)-isopropyl 7-((R)-2-((R,E)-4-(3-chlorophenoxy)-3-hydroxybut-l-eny1)-5-oxocyclopent-2-enyl) hept-5-enoate, (Z)-7-((R)-2-((R,E)-4-(3-chlorophenoxy)-3-hydroxybut-l-eny1)-5-oxocyclopent-2-enyl) -N-methylhept-5-enamide or a pharmaceutically acceptable salt, hydrate, solvate, prodrug or metabolite thereof. These agents may be used alone or in combination, and may be administered concurrently or sequentially. See also, 2011/0144160, 2011/0130453, 2011/0112134, 2011/0098352, 2011/0098302, 2011/0071175, 2011/0060026, 2011/0034558, 2011/0028717, 2011/0021599, 2011/0021573, 2011/0002866, 2010/0330077, each of which is expressly incorporated herein by reference.
- This invention describes, for example, methods to apply and correlate the clinical measurement of L-PGDS concentrations of cervical vaginal secretions from pregnant women with the attendant likelihood of term or preteen delivery.
- The invention also describes methods and compositions, specifically prostaglandin D2 (DP1 and DP2) receptor antagonists or inhibitors, as potential tocolytic agents.
- It is therefore an object to provide a method for assessing the likelihood of preterm delivery for a pregnant woman, the method comprising collecting a cervical vaginal secretion sample from a pregnant woman; and measuring lipocalin-type prostaglandin D2 synthase (L-PGDS) concentration levels from the sample, wherein L-PGDS concentration levels correlate to and indicate an above or below average likelihood relative to the relevant standard population for preterm delivery.
- According to one embodiment, an L-PGDS concentration level higher than 1.8 μg/ml indicates an increased likelihood for preterm delivery.
- The method may advantageously be applied to a pregnant woman has intact amniotic membranes.
- The cervical vaginal secretion may be collected with a sponge.
- Based on the L-PGDS level, at least one prostaglandin D2 receptor antagonist may be administered as a tocolytic agent. The at least one prostaglandin D2 receptor antagonist may comprises a DPI receptor antagonist and/or a DP2 receptor antagonist.
- The L-PGDS concentration level may be determined using an antibody sandwich Enzyme-Linked ImmunoSorbent Assay (ELISA). The L-PGDS concentration levels may be normalized to protein levels in the cervical vaginal secretions for analysis.
- Another object provides a method for treatment of preterm labor, comprising administration of a therapeutic amount of at least one prostaglandin DPI or prostaglandin DP2 receptor antagonist to a pregnant woman such that preterm delivery is avoided or mitigated.
- The administration may be selectively in dependence on a measured L-PGDS level, for example in a cervical vaginal secretion.
- The at least one prostaglandin DP1 or prostaglandin DP2 receptor antagonist comprises one or more agents selected from the group consisting of AM156 ({2′-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-6-methoxy-4′-trifluoro-methyl-biphenyl-3-y11-acetic acid, sodium salt), and AM206 {2-Rbenzoyloxycarbonyl-ethyl-amino)-methy11-4-trifluoromethyl-phenyll-pyridin-3-yl)-acetic acid, sodium salt), MK-0524 ([(3R)-4-(4-Chloro-benzyl)-7-fluoro-5-(tnethylsulfony1)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yThacetie Acid), AM-853 (2-(4-(4-(tert-butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenyl sulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid), BW868C (3-benzyl-5-(6-carbohexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)-hydantoin), S-5751 ((Z)-7-[(1R,2R,3S,5S)-2-(5-hydroxy benzo[b]thiophen-3-ylearbonylamino)-10-norpinan-3-ylihept-5-enoic acid), and BAY-u3405 (Ramatroban, 3(R)-[[(4-fluorophenyl) sulphonyl]amino]-1 ,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid).
- Alternately, an L-PGDS inhibitor may be used, for example, AT-56 (4-dibenzo[a,d]cyclohepten-5-ylidene-1-[4-(2H-tetrazol-5-yl)-butyl]-piperidine).
- Resveratrol has been shown to reduce formation of Prostaglandin D2 presumably by inhibiting cyclooxygenase (COX), especially COX-2. See, Lena Wendeburg, Antonio Carlos Pinheiro de Oliveira, Harsharan S Bhatia, Eduardo Candelario-Jalil and Bernd L Fiebich, “Resveratrol inhibits prostaglandin foiniation in IL-1β-stimulated SK-N-SH neuronal cells”, J. Neuroinflammation 2009, 6:26, expressly incorporated herein by reference. Therefore, resveratrol or another non-teratogenic COX-2 inhibitor may advantageously be employed.
- The at least one prostaglandin DP1 or prostaglandin DP2 receptor antagonist is administered orally, by inhalation, through a mucous membrane, transdermally, topically, rectally, or parenterally.
- The at least one prostaglandin DP1 or prostaglandin DP2 receptor antagonist may be administered to achieve concurrent therapeutic effect with another tocolytic agent which is not a prostaglandin D2 receptor antagonist. For example, the other tocolytic agent may comprise a β2 agonist, such as terbutaline, Ritodrine, Fenoterol, or Salbutamol. The other tocolytic agent may also comprise a non-steroidal anti-inflammatory drug cyclooxygenase inhibitor, such as Indomethicin or sulindac. The tocolytic may be a calcium channel blocker, such as nifedipine, a myosin light chain inhibitor such as magnesium sulfate, or an axytocin inhibitor such as Atosiban.
- A further object provides a pharmaceutical formulation comprising a therapeutic amount of a non-teratogenic comprising at least one prostaglandin DP1 or prostaglandin DP2 receptor antagonist and/or an L-PGDS inhibitor, in an effective amount to delay preterm delivery in a pregnant human when administered in repeated doses. The at least one prostaglandin DP1 or prostaglandin DP2 receptor antagonist may comprise, for example, one or more agents selected from the group consisting of AM156 ({2′-[(cyclopropanecarbonyl-ethyl-amino)-methy1]-6-methoxy-4′-trifluoro-methyl-biphenyl-3-yll-acetic acid, sodium salt), and AM206 (5-{2-[(benzoyloxycarbonyl-ethyl-amino)-methyl]-4-trifluoromethyl-phenyll-pyridin-3-yl)-acetic acid, sodium salt), MK-0524 ([(3R)-4-(4-Chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-y11-acetic Acid), AM-853 (2-(4-(4-(tert-butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenyl sulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid), BW868C (3-benzyl-5-(6-carbohexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)-hydantoin), S-5751 ((Z)-7-[(1R,2R,3S,5S)-2-(5-hydroxy benzo[b]thiophen-3-yIcarbonylamino)-10-norpinan-3-yl]hept-5-enoic acid), and BAY-u3405 (Ramatroban, 3(R)-[[(4-fluorophenyl) sulphonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid), and the L-PGDS inhibitor may comprise AT-56 (4-dibenzo[a,d]eyelohepten-5-ylidene-144-(2H-tetrazol-5-yl)-butyl]-piperidine).
- All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
- The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
-
FIGS. 1A and 1B present data from a preliminary study of samples of pregnant women correlating L-PGDS levels in cervical vaginal secretions with term or preterm delivery. -
FIG. 2 present data from a study of samples of pregnant women correlating L-PGDS levels in cervical vaginal secretions with term or preterm delivery. -
FIG. 3 presents data from (murine) animal studies to demonstrate the relationship between lower L-PGDS levels and likelihood of viability and successful term birth. -
FIG. 4 shows 2D PAGE of Human CVS L-PGDS Isoforms. - Cervical vaginal secretions (CVS) arc readily collected and constitute a′ minimally invasive procedure. During a sterile speculum examination of a pregnant woman, a Week-gel sponge is applied into the cervical os for approximately one minute. The sponge is then removed and placed in a buffer solution containing physiological saline, Trizma buffer, protease inhibitors (EDTA, phenylmethylsulfonyl fluoride, pepstatin) and antibacterial agents (such as sodium azide). This sample collection process is very similar to that used for other routine clinical assays (e.g., fetal fibronectin) that use cervical secretions for the starting sample material. Preferably, the buffer solution has a low protein concentration, e.g., is produced with a small amount or no bovine serum albumin (BSA). This BSA is not required to stabilize the L-PGDS, and may interfere with its measurement.
- L-PGDS concentration levels from the cervical vaginal secretion samples are then determined by an antibody sandwich ELISA. As an initial step, antibody against L-PGDS raised in rabbits is purified by hydroxyapatite chromatography, followed by an immunoaffinity purification on an Affi-Gel 15 Gel column.
- The purified antibody is then diluted to 10 μg/ml in 0.2M sodium carbonate buffer, pH 9.0, and 50 μl added to each well of an Nunc-Immuno plate with Maxi Sorp surface overnight at 4° C. The wells are then washed with 0.1% BSA/0.05% Tween 20 in
PBS 4 times and blocked with 1% BSA in PBS for 1 hour. Diluted plasmas or L-PGDS standards (1.2 to 75 ng/ml) are incubated in Block for 90 minutes, then washed as above. A secondary anti-L-PGDS antibody, raised in chickens, at 4 ng/ml in wash buffer, is incubated in the wells for 1 hour and then washed, as above. Horseradish peroxidase-tagged goat anti-chicken antibody at 1:10,000 in wash buffer is added for 1 hour and then the plate is washed, as above, developed in a 0.01 3,3′, 5,5′ tetramethylbenzidine solution, stopped with 50 μl of IN sulfuric acid, and read at 450 nm in a microplate reader. L-PGDS concentration is determined by the standard curve obtained by plotting the absorbance versus the corresponding concentration of an L-PGDS standard. - This assay is also adapted to a BioPlex suspension array for similar quantitation. The assay is also amenable for development to run the samples on a 2-D PAGE and determine the particular L-PGDS isoforms present/absent from the CVS samples that may be indicative of an increased propensity toward preterm birth. It is understood and believed that an antibody to the specific isoform may be created to fine-tune the detection method.
- In assessing test samples, L-PGDS concentrations determined by ELISA are normalized to protein levels in the CVS. Protein content of the samples is determined by BCA method, which has been commonly used to quantitate protein levels in cell lysates.
- The new markers of the present invention are highly sensitive and specific (e.g., 90% or higher). In an preliminary study, at a level of 90% specificity, the sample size yields a 95% confidence level, indicating high precision, with a margin of error of about 5%. The collection of test data from pregnant women is ongoing and studies producing significant results have been established as demonstrated in the following Table 1.
-
TABLE 1 CVS L-PGDS (ng/ml) Term Preterm Patient CVS Term Days to Patient CVS Preterm Days to ID # (weeks) Delivery Delivery ID # (weeks) Delivery Delivery 17 26 607 84 20 30 7653 11 19 26 725 86 21 30 4839 24 24 26 818 93 23 32 2589 2 26 31 1163 58 28 28 1033 2 27 33 282 32 30 32 4926 1 29 25 782 85 31 25 872 33 30 1798 57 34 29 2717 66 36 25 1056 37 27 1308 MEAN 28 1103 70 MEAN 30 4208 8 SEM 1 201 6 SEM 1 761 3 Notes: Current samples collected at between 28-30 weeks of gestation Level of L-PGDS -4-fold higher than in pregnancies that go to term Average time until delivery based on elevated L- PGDS 8 days vs. 70 days with lower levelsCurrently a cutoff of <1.8 μg/ml L-PGDS would appear to distinguish ~91% of term deliveries - Statistical analysis of this data indicates that high L-PGDS levels (i.e., L-PGDS levels above 1.8μ/ml) predict an increased likelihood of preterm delivery in human subjects. Graphical illustration of this analysis is depicted in
FIGS. 1A and 1B . Findings from the studies indicate that L-PGDS levels in pregnant women susceptible to preterm delivery average a 4-fold increase over levels in women whose pregnancies go to term, and that the average time until delivery for women with elevated L-PGDS levels is 8 days, compared to 70 days for those women that do not demonstrate such elevated levels. - The pattern of elevated L-PGDS in preterm is generally consistent with the predicted rise. Because the L-PGDS level has a normal change over gestation, CVS samples are preferably taken and L-PGDS assays performed every two weeks.
- A key advantage of this assay over the current fetal fibronectin (fFN) test is that the present assay would predict preterm birth over the entire gestational period up to parturition. A negative fFN, although very accurate, is only valid for a 2-week window. Interestingly, in the study reported below, there were several samples that were fFN negative, but ultimately went preterm. The present assay showed elevated L-PGDS, and was predictive for preterm birth.
-
FIG. 2 shows results from a larger study. The data shows that for 163 patients, 36 were preterm (birth less than 37 weeks gestation), with a median of L-PGDS of 8,566 ng/ml/ng protein and 127 went to term with an median of 28,247 ng/ml/ng protein. Results showed that difference in the median values between the two groups is greater than would be expected by chance; there is a statistically significant difference (P=<0.001). See Table 2. -
TABLE 2 Mann-Whitney Rank Sum Test Group N Missing Median 25% 75 % Preterm 36 0 28247.587 17051.503 47944.682 Term 127 0 8566.720 4663.511 12857.063 Mann-Whitney U Statistic = 694.000 T = 4544.000 n(small) = 36 n(big) = 127 (P = <0.001) - The difference in the median values between the two groups is greater than would be expected by chance; there is a statistically significant difference (P=<0.001)
- Animal studies conducted to determine the correlations between L-PGDS concentrations and birth viability and/or risk of preterm birth were conducted with L-PGDS knockout mice and transgenic L-PGDS overexpressor mice. Results are demonstrated in
FIG. 3 . The studies strongly validate the present findings that lower concentration levels of L-PGDS tend to increase the chances of successful term birth, as per the present murine model. The findings from these animal studies cross-validate the findings from human studies (e.g., as presented above in Table 1). - Table 3 shows data demonstrating that in LPS-induced preterm birth, there is a three-fold increase in viable mouse pups/pregnancy in the L-PGDS knockouts and a 15-fold decrease in viable pups/pregnancy in the L-PGDS transgenic overexpressors when compared to the C57BL/6 controls. This implies that L-PGDS is casually related to preterm birth, and not merely correlated with it.
-
TABLE 3 C57BL/6 L- PGDS KO L- PGDS KI Experiment # 1 2 3 4 5 Total SEM 1 2 3 4 5 Total SEM 1 2 3 4 5 Total SEM Pregnant 2 4 3 5 3 17 0.5 0 3 2 3 2 10 0.5 0 1 4 4 6 15 1.1 Females Viable Pups 1 5 0 5 7 18 1.3 0 8 9 16 0 33 3.0 0 0 0 1 0 1 0.2 Adverse 15 19 21 12 10 77 2.1 0 2 1 11 2 16 2.0 0 4 23 25 56 108 9.9 Outcome Viable Pups/ 1.06 3.30 0.07 Pregnancy - In a study of pregnant C57BL/6 mice implanted with Alzet osmotic pumps containing both DP1 and DP2 antagonists (BWA868C and 11-deoxy-11-methylene prostaglandin D2 at 1.0 μg/μl or PBS vehicle) were injected with lipopolysaccharide (LPS) (20 μg) at day 14 of pregnancy to induce preterm birth. In the LPS-only control group, 80% suffered adverse outcomes (premature birth or fetal death), and 20% had normal outcomes. In the experimental group, LPS plus DP1 and DP2 antagonist, 50% suffered adverse outcomes and 50% had normal outcomes. This demonstrates that administration of prostaglandin D2 receptor antagonists may be administered to pregnant mammals to interrupt preterm labor, and more particularly, to avoid preterm labor induced by infectious agents, especially those which produce lipopolysaccharides. Because the preterm labor pathway has common elements, it is likely that the prostaglandin D2 receptor antagonists will also act to block preterm labor from other causes.
- Chemical compounds which influence the levels of L-PGDS in pregnant women might be administered as tocolytic therapeutic agents. Preferred embodiments of such effective tocolytic agents include prostaglandin D2 (DP1 or DP2) receptor antagonists, such as BWA868C, see, e.g., U.S. Pat. Nos. 6,395,499; 6,878,522; 6,884,593; 7,144,913; 7,217,725; 7,517,889; 7,642,249; 8,067,445; 8,383,654; 8,426,449; 8,497,381; 8,071,807; 8,193,183; 8,242,145; 8,338,484; 8,362,044; 8,378,107; 8,501,959; 8,524748; U.S. Pat Pub. Nos. 20020022218; 20030027854; 20040162323; 20040180934; 20040185509; 20040197834; 20050215609; 20070054951; 20070244131; 20070249686; 20070265278; 20070265291; 20080194600; 20080261922; 20090036469; 20090176804; 20090197959; 20100004331; 20100075990; 20100081673; 20100113503; 20100130574; 20100298368; 20110021573; 20110039852; 20110098302; 20110098352; 20110112134; 20110130453; 20110144160; 20110152338; 20110190227; 20110245303; 20110301168; 20110312974; 20110318308; 20110319445; 20120004233; 20120016029; 20120022119; 20120058123; 20120059055; 20130005728; 20130005741; 20130065902; 20130079375; 20130109685; 20130158036; each of which is expressly incorporated herein by reference. Methods of treatment and preventing preterm delivery include the administration of a therapeutic amount of prostaglandin D2 receptor antagonists to a pregnant woman in need thereof. Proper routes of administration, dosages and frequencies of administration of these tocolytic agent prostaglandin D2 receptor antagonists may be readily determined by one of skill in the art, e.g., medical practitioners.
- More particularly, the present invention provides for methods of treating preterm labor via the administration of pharmaceutical compositions comprising active tocolytic therapeutic agents with a pharmaceutically acceptable carrier. Pharmaceutical composition of the present invention are intended to encompass a product comprising the active ingredient(s), e.g., prostaglandin D2 receptor antagonists, and the inert ingredient(s) (pharmaceutically acceptable excipients) that constitute the carrier, as well as any product which may result, directly or indirectly, from combination, complex formation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or form other types of reactions or interactions of one or more of the ingredients.
- For example, available prostaglandin D2 (DP1/DPGTR, DP2/CRTH2) receptor antagonists include AM156 (12′-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-6-methoxy-4′-trifluoro-methyl-biphenyl-3-yl}-acetic acid, sodium salt), and AM206 (5-{2-[(benzoyloxycarbonyl-ethyl-amino)-methyl]-4-trifluoromethyl-phenyl-pyridin-3-yl)-acetic acid, sodium salt), MK-0524 ([(3R)-4-(4-Chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indo1-3-yl]-acetic Acid), AM-853 (2-(4-(4-(tert-butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenyl sulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid), BW868C (3-benzyl-5-(6-carbohexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)-hydantoin), S5751 ((Z)-7-[(1R,2R,3S,5S)-2-(5-hydroxy benzo[b]thiophen-3-ylcarbonylamino)-10-norpinan-3-yl]hept-5-enoic acid), BAY-u3405 (Ramatroban, 3(R)-[[(4-fluorophenyl) sulphonyl]aminol-1,2,3,4- tetrahydro-9H-carbazole-9-propanoic acid). Such agents, or others that are known or become known, may be used alone, in combination or subcombination. In some cases, the effects may be enhanced by selectively acting on DP1 or DP2, and therefore appropriate agents may be selected. Likewise, as may be appropriate, a mixed agonist/antagonist comprising a single or multiple agents, may be administered or concurrently administered.
- For the treatment of preterm labor, the tocolytic therapeutic agents may be administered orally, by inhalation spray, topically, transdermally, parenterally or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. Tocolytic therapeutic agents, e.g., prostaglandin D2 receptor antagonists, may be co-administered with other therapeutic agents and are suitable for simultaneous and/or sequential combination therapies. Methods of the present invention further encompass co-administration to a pregnant woman of a non-toxic therapeutically effective amount of a tocolytic therapeutic agent, such as a prostaglandin D2 receptor antagonist, optionally with other active therapeutic agents, e.g., other prostaglandin D2 receptor antagonists, either simultaneously or sequentially as part of a combination therapy treatment regimen. Similarly, a selective L-PGDS inhibitor, such as AT-56 (4-dibenzo[a,d]cyclohepten-5-ylidene-144-(2H-tetrazol-5-yl)-butyl]-piperidine) may be used alone or in combination with a DP1 and/or a DP2 antagonist. The therapeutic amounts of active therapeutic agents as administered in combination therapy may be those as commonly used for each active therapeutic agent when administered alone, or the amounts may result in lower dosage(s) for one or more of the active therapeutic agents.
- As shown in
FIG. 4 , different isoforms of L-PGDS appear in preterm birth CVS samples than for at term births. Therefore, a selective immunoassay may be implemented based on the ability of certain antibodies to distinguish between the isoforms. Immunoassays may include radio immunoassays, enzyme-linked immunoassays, fluorescent immunoassays, and the like. - On the other hand in a ratiometric assay which seeks to determine a ratio between isoforms, or between a single isoform and the total, during purification, it may be preferred to avoid selective enrichment, and thus immunopurification may employ a non-specific antibody or a balanced mix of antibodies to ensure that the CVS sample concentrations are not altered during processing. Although the present invention has been described in relation to particular embodiments thereof, many other variations and modifications and other uses will become apparent to those skilled in the art. It is preferred, therefore, that the present invention be limited not by the specific disclosure herein, but only by the appended claims.
- While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/523,832 US20200018753A1 (en) | 2012-10-24 | 2019-07-26 | Non-invasive biomarker to identify subject at risk of preterm delivery |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261717724P | 2012-10-24 | 2012-10-24 | |
PCT/US2013/066490 WO2014066568A1 (en) | 2012-10-24 | 2013-10-24 | Non-invasive biomarker to identify subjects at risk of preterm delivery |
US201514438110A | 2015-04-23 | 2015-04-23 | |
US15/708,582 US10408838B2 (en) | 2012-10-24 | 2017-09-19 | Non-invasive biomarker to identify subject at risk of preterm delivery |
US16/523,832 US20200018753A1 (en) | 2012-10-24 | 2019-07-26 | Non-invasive biomarker to identify subject at risk of preterm delivery |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/708,582 Continuation US10408838B2 (en) | 2012-10-24 | 2017-09-19 | Non-invasive biomarker to identify subject at risk of preterm delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200018753A1 true US20200018753A1 (en) | 2020-01-16 |
Family
ID=49515574
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/438,110 Active US9797903B2 (en) | 2012-10-24 | 2013-10-24 | Non-invasive biomarker to identify subject at risk of preterm delivery |
US15/708,582 Active US10408838B2 (en) | 2012-10-24 | 2017-09-19 | Non-invasive biomarker to identify subject at risk of preterm delivery |
US16/523,832 Abandoned US20200018753A1 (en) | 2012-10-24 | 2019-07-26 | Non-invasive biomarker to identify subject at risk of preterm delivery |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/438,110 Active US9797903B2 (en) | 2012-10-24 | 2013-10-24 | Non-invasive biomarker to identify subject at risk of preterm delivery |
US15/708,582 Active US10408838B2 (en) | 2012-10-24 | 2017-09-19 | Non-invasive biomarker to identify subject at risk of preterm delivery |
Country Status (4)
Country | Link |
---|---|
US (3) | US9797903B2 (en) |
EP (2) | EP2912458B1 (en) |
ES (1) | ES2690782T3 (en) |
WO (1) | WO2014066568A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014066568A1 (en) | 2012-10-24 | 2014-05-01 | Winthrop-University Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
ES2955883T3 (en) * | 2015-06-19 | 2023-12-07 | Sera Prognostics Inc | Biomarker pairs for the prediction of preterm birth |
WO2017161222A1 (en) * | 2016-03-17 | 2017-09-21 | The Trustees Of Columbia University In The City Of New York | The use of inhibitors of calcium-activated chloride channels to prevent and treat preterm labor, alone or in combination with other tocolytic agents |
WO2019036032A1 (en) | 2017-08-18 | 2019-02-21 | Sera Prognostics, Inc | Pregnancy clock proteins for predicting due date and time to birth |
CA3075688A1 (en) | 2017-09-13 | 2019-03-21 | Progenity, Inc. | Preeclampsia biomarkers and related systems and methods |
US10431281B1 (en) | 2018-08-17 | 2019-10-01 | Micron Technology, Inc. | Access schemes for section-based data protection in a memory device |
US10991411B2 (en) | 2018-08-17 | 2021-04-27 | Micron Technology, Inc. | Method and apparatuses for performing a voltage adjustment operation on a section of memory cells based on a quantity of access operations |
EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | Assessment of preeclampsia using assays for free and dissociated placental growth factor |
Family Cites Families (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223440A (en) | 1987-11-17 | 1993-06-29 | Adeza Biomedical Corporation | Ex vivo product of conception test to determine abortion |
US5096830A (en) | 1987-11-17 | 1992-03-17 | Adeza Biomedical Corporation | Preterm labor and membrane rupture test |
US5281522A (en) | 1988-09-15 | 1994-01-25 | Adeza Biomedical Corporation | Reagents and kits for determination of fetal fibronectin in a vaginal sample |
US4919889A (en) | 1988-09-15 | 1990-04-24 | Aspen Diagnostics Corporation | Sample collection and transport fluid composition |
EP0642667B1 (en) * | 1991-11-04 | 2001-01-10 | Adeza Biomedical Corporation | Screening method for identifying women at increased risk for preterm delivery |
WO1993009432A1 (en) | 1991-11-04 | 1993-05-13 | Adeza Biomedical Corporation | Screening method for identifying women at increased risk for imminent delivery |
US5516702A (en) | 1991-11-06 | 1996-05-14 | Adeza Biomedical Corporation | Screening method for identifying women at increased risk for imminent delivery |
DE69431621D1 (en) | 1993-03-23 | 2002-12-05 | Victor Voroteliak | METHOD FOR DETECTING TREES IN AMNIOMEMBRANES IN PREGNANT MAMMALS |
US5431171A (en) | 1993-06-25 | 1995-07-11 | The Regents Of The University Of California | Monitoring fetal characteristics by radiotelemetric transmission |
US5650394A (en) | 1993-11-04 | 1997-07-22 | Adeza Biomedical | Use of urinastatin-like compounds to prevent premature delivery |
US5597700A (en) | 1994-04-28 | 1997-01-28 | California Research, Llc | Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method |
US6140099A (en) | 1994-05-20 | 2000-10-31 | The Trustees Of The University Of Pennsylvania | Method of delaying fetal membrane rupture by inhibiting matrix metalloproteinase-9 activity |
US5641636A (en) | 1994-05-20 | 1997-06-24 | University Of Pennsylvania | Method of predicting fetal membrane rupture based on matrix metalloproteinase-9 activity |
JP3064015B2 (en) | 1995-01-26 | 2000-07-12 | メルク フロスト カナダ アンド カンパニー | Prostaglandin receptor DP |
ATE315048T1 (en) * | 1995-10-31 | 2006-02-15 | Maruha Corp | MONOCLONAL ANTIBODY SPECIFIC FOR PROSTAGLANDIN D SYNTHETASE |
US6678669B2 (en) | 1996-02-09 | 2004-01-13 | Adeza Biomedical Corporation | Method for selecting medical and biochemical diagnostic tests using neural network-related applications |
US6544193B2 (en) | 1996-09-04 | 2003-04-08 | Marcio Marc Abreu | Noninvasive measurement of chemical substances |
US6120460A (en) | 1996-09-04 | 2000-09-19 | Abreu; Marcio Marc | Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions |
US6875567B1 (en) | 1997-11-10 | 2005-04-05 | Genentech, Inc. | Method of detecting cardiac hypertrophy through probe hybridization and gene expression analysis |
US6610480B1 (en) | 1997-11-10 | 2003-08-26 | Genentech, Inc. | Treatment and diagnosis of cardiac hypertrophy |
US20020031513A1 (en) | 1997-11-24 | 2002-03-14 | Shamir Leibovitz | Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals |
US6267722B1 (en) | 1998-02-03 | 2001-07-31 | Adeza Biomedical Corporation | Point of care diagnostic systems |
US6394952B1 (en) | 1998-02-03 | 2002-05-28 | Adeza Biomedical Corporation | Point of care diagnostic systems |
US6506789B2 (en) | 1998-06-03 | 2003-01-14 | Shionogi & Co., Ltd. | Methods for the treatment of itching comprising administering PGD2 receptor antagonist |
US6149590A (en) | 1998-07-22 | 2000-11-21 | Smith; Ramada S. | System for identifying premature rupture of membrane during pregnancy |
US20010025140A1 (en) | 1998-07-22 | 2001-09-27 | Torok Brian A. | System for identifying premature rupture of membrane during pregnancy |
US6126597A (en) | 1998-07-22 | 2000-10-03 | Smith; Ramada S. | System for identifying premature rupture of membrane during pregnancy |
US7109044B1 (en) | 1998-09-04 | 2006-09-19 | Maruha Corporation | Method of detection and disease state management for renal diseases |
BR9915820A (en) | 1998-10-29 | 2001-10-30 | Univ Texas | Clinical use of thiazolidinediones alone or in conjunction with other agents to block oxytocin-mediated actions, such as uterine contractions in premature birth or lactation |
JP2000249709A (en) | 1999-02-26 | 2000-09-14 | Maruha Corp | Predicting method for restenosis after coronary blood vessel intervention execution |
US6126616A (en) | 1999-06-21 | 2000-10-03 | Sanyal; Mrinal K. | Collection of biological products from human accessory reproductive organs by absorbent systems |
WO2001014882A1 (en) | 1999-08-23 | 2001-03-01 | Bml, Inc. | Method of identifying properties of substance to prostaglandin d receptors |
FR2809182B1 (en) | 2000-05-18 | 2003-08-15 | Univ Rene Descartes | DETECTION OF IL-6 FOR PREDICTING PREMATURE DELIVERY RISKS |
US20010053876A1 (en) | 2000-06-15 | 2001-12-20 | Torok Brian A. | System for identifying premature rupture of membrane during pregnancy |
US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
CA2417669C (en) | 2000-07-21 | 2009-09-15 | Maruha Corporation | Methods for differentiating demential diseases |
US6410583B1 (en) | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
AU2001288410A1 (en) | 2000-08-28 | 2002-03-13 | Patrick G. Morand | Use of blood and plasma donor samples and data in the drug discovery process |
US7217725B2 (en) | 2000-09-14 | 2007-05-15 | Allergan, Inc. | Prostaglandin D2 antagonist |
DE60215000T2 (en) | 2001-05-23 | 2007-08-09 | Merck Frosst Canada & Co, Kirkland | Dihydropyrroloil [1,2-a] indole and tetrahydropyridol [1,2-a] indole derivatives as prostaglandin D2 receptor antagonists |
CA2454347A1 (en) | 2001-07-18 | 2003-01-30 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | Eosinophil prostaglandin d2 receptor assays |
US20040197834A1 (en) | 2001-07-20 | 2004-10-07 | Francois Gervais | Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors |
US20050101841A9 (en) | 2001-12-04 | 2005-05-12 | Kimberly-Clark Worldwide, Inc. | Healthcare networks with biosensors |
US20060166295A1 (en) | 2002-07-01 | 2006-07-27 | James Woods | Method for determination of likelihood of occurrence of preterm labor in pregnant females |
CA2533915C (en) | 2002-08-13 | 2020-09-22 | N-Dia, Inc. | Devices and methods for detecting amniotic fluid in vaginal secretions |
US7488585B2 (en) | 2002-08-29 | 2009-02-10 | Diagnostic Technologies Ltd. | Method of diagnosis of pregnancy-related complications |
EP1547598A1 (en) | 2002-09-30 | 2005-06-29 | Shionogi & Co., Ltd. | NOVEL USES OF PROSTAGLANDIN D sb 2 /sb , PROSTAGLANDIN D sb 2 /sb AGONIST AND PROSTAGLANDIN D sb 2 /sb ANTAGONIST |
AU2003284166A1 (en) | 2002-10-23 | 2004-05-13 | University Of Hawaii | Methods for diagnosing and treating pre-term labor |
US20040100376A1 (en) | 2002-11-26 | 2004-05-27 | Kimberly-Clark Worldwide, Inc. | Healthcare monitoring system |
AU2003290773A1 (en) | 2003-02-05 | 2004-09-06 | Ciphergen Biosystems, Inc. | Non-invasive assessment of intra-amniotic environment |
WO2004071427A2 (en) | 2003-02-06 | 2004-08-26 | Adeza Biomedical Corporation | Screening and treatment methods for prevention of preterm delivery |
US7191068B2 (en) | 2003-03-25 | 2007-03-13 | Proteogenix, Inc. | Proteomic analysis of biological fluids |
US8068990B2 (en) | 2003-03-25 | 2011-11-29 | Hologic, Inc. | Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids |
US20040203079A1 (en) | 2003-04-09 | 2004-10-14 | Research Foundation Of The State University Of New York | Methods and kits for detecting cerebrospinal fluid in a sample |
US20070003992A1 (en) | 2003-04-09 | 2007-01-04 | Pentyala Srinivas N | Methods and kits for detecting cerebrospinal fluid in a sample |
US8003765B2 (en) | 2003-04-09 | 2011-08-23 | Stony Brook Anaesthesiology, University Faculty Practice Corporation | Methods, antibodies and kits for detecting cerebrospinal fluid in a sample |
EP1620006A4 (en) | 2003-05-02 | 2009-12-02 | Univ Johns Hopkins | Devices, systems and methods for bioimpendence measurement of cervical tissue and methods for diagnosis and treatment of human cervix |
US20070054951A1 (en) | 2003-05-20 | 2007-03-08 | Lianhai Li | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists |
WO2005007223A2 (en) | 2003-07-16 | 2005-01-27 | Sasha John | Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations |
JP3897117B2 (en) | 2003-09-24 | 2007-03-22 | マルハ株式会社 | Method for determining and predicting the severity of pregnancy toxemia, and for evaluating fetal / placental function in pregnancy toxemia |
US20080233597A1 (en) | 2003-09-26 | 2008-09-25 | Yasuhiko Shiina | Method of Detecting or Differentiating Rheumatoid Arthritis and Method of Determining Stage of Disease or Degree of Dysfunction with Regard to Rheumatoid Arthritis |
US20050131287A1 (en) | 2003-12-16 | 2005-06-16 | Kimberly-Clark Worldwide, Inc. | Detection of premature rupture of the amniotic membrane |
EP2299275B1 (en) | 2004-07-30 | 2018-03-07 | Adeza Biomedical Corporation | Classification of the oncofetal fibronection level for pregnancy-related indications |
US20080254479A1 (en) | 2004-08-30 | 2008-10-16 | Cervimark, Llc | Methods and Kits For Predicting Risk For Preterm Labor |
US20080090759A1 (en) | 2004-08-30 | 2008-04-17 | Robert Kokenyesi | Methods and kits for predicting risk for preterm labor |
GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
HN2005000795A (en) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | PYRIMIDINS AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEPTOR |
CA2528531A1 (en) | 2005-01-06 | 2006-07-06 | Mount Sinai Hospital | Markers of pre-term labor |
DOP2006000016A (en) | 2005-01-26 | 2006-07-31 | Aventis Pharma Inc | 2-PHENYL-INDOLES AS ANTAGONISTS OF THE PROSTAGLANDIN RECEPTOR D2. |
GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
US20070128589A1 (en) | 2005-07-13 | 2007-06-07 | Sanders Mitchell C | Substrates, sensors, and methods for assessing conditions in females |
EP1911759A4 (en) | 2005-07-22 | 2010-07-21 | Shionogi & Co | Azaindole derivative having pgd2 receptor antagonistic activity |
CN101309929A (en) | 2005-09-15 | 2008-11-19 | 创源生物科技(武汉)有限公司 | A marker for prolonged rupture of membranes |
GT200600457A (en) | 2005-10-13 | 2007-04-27 | Aventis Pharma Inc | DIHYDROGEN PHOSPHATE SALT AS ANTAGONIST OF PROSTAGLANDINA D2 RECEPTOR |
US8076315B2 (en) | 2005-10-14 | 2011-12-13 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists |
US20080009552A1 (en) | 2006-03-23 | 2008-01-10 | Craig Pennell | Markers of pre-term labor |
AR060403A1 (en) | 2006-04-12 | 2008-06-11 | Sanofi Aventis | AMINO COMPOUNDS- PYRIMIDINE 2.6- SUBSTITUTES -4- MONOSUSTITUTES AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEIVER |
DK2037967T3 (en) | 2006-06-16 | 2017-03-13 | Univ Pennsylvania | PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI |
PT2066628E (en) | 2006-07-25 | 2010-12-31 | Sanofi Aventis | 2-phenyl-indoles as prostaglandin d2 receptor antagonists |
US8133859B2 (en) | 2006-09-27 | 2012-03-13 | The United States Of America As Represented By The Department Of Health And Human Services | SCGB3A2 as a growth factor and anti-apoptotic agent |
EP2083863B1 (en) | 2006-10-03 | 2015-03-18 | Genzyme Corporation | Antibodies to tgf-beta for use in the treatment of infants at risk of developing bronchopulmonary dysplasia |
WO2008073491A1 (en) | 2006-12-11 | 2008-06-19 | University Of Florida Research Foundation, Inc. | System and method for analyzing progress of labor and preterm labor |
WO2008075172A2 (en) | 2006-12-19 | 2008-06-26 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
AU2007338634A1 (en) | 2006-12-26 | 2008-07-03 | Brigham Young University | Serum proteomics system and associated methods |
EP2132196A1 (en) | 2007-02-26 | 2009-12-16 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
US20090058072A1 (en) | 2007-08-30 | 2009-03-05 | Shirlee Ann Weber | Record sheets with integrated themes |
US20100251394A1 (en) | 2007-09-20 | 2010-09-30 | The Johns Hopkins University | Treatment and prevention of ischemic brain injury |
WO2009059259A2 (en) | 2007-10-31 | 2009-05-07 | Children's Hospital Medical Center | Detection of worsening renal disease in subjects with systemic lupus erythematosus |
US20110002866A1 (en) | 2007-10-31 | 2011-01-06 | Lubit Beverly W | Methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent |
WO2009061681A2 (en) | 2007-11-06 | 2009-05-14 | Amira Pharmaceuticals, Inc | Antagonists of pgd2 receptors |
US20110065139A1 (en) | 2007-11-27 | 2011-03-17 | Jacob Mullerad | diagnostic device for identifying rupture of membrane during pregnancy |
US20130177485A1 (en) | 2007-11-27 | 2013-07-11 | Momtec Life Ltd. Of Yazmot Haemek | Diagnostic device for identifying rupture of membrane during pregnancy |
CA2707785C (en) | 2007-12-14 | 2015-11-03 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
US20110060026A1 (en) | 2008-01-18 | 2011-03-10 | George Hynd | Indoles Active on CRTH2 Receptor |
WO2009097579A1 (en) | 2008-01-30 | 2009-08-06 | Proteogenix, Inc. | Gestational age dependent proteomic changes of human maternal serum for monitoring maternal and fetal health |
KR101235961B1 (en) | 2008-02-01 | 2013-02-21 | 판미라 파마슈티칼스, 엘엘씨 | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors |
US20110098352A1 (en) | 2008-02-01 | 2011-04-28 | Amira Pharmaceuticals, Inc. | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors |
US8242145B2 (en) | 2008-02-14 | 2012-08-14 | Panmira Pharmaceuticals, Llc | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors |
JP2011513242A (en) | 2008-02-25 | 2011-04-28 | アミラ ファーマシューティカルズ,インク. | Prostaglandin D2 receptor antagonist |
WO2009145989A2 (en) | 2008-04-02 | 2009-12-03 | Amira Pharmaceuticals, Inc. | Aminoalkylphenyl antagonists of prostaglandin d2 receptors |
US20110166070A1 (en) | 2008-05-16 | 2011-07-07 | Stewart Dennis R | Method of preventing premature delivery |
US20110112134A1 (en) | 2008-05-16 | 2011-05-12 | Amira Pharmaceuticals, Inc. | Tricyclic Antagonists of Prostaglandin D2 Receptors |
JP2011526281A (en) | 2008-06-24 | 2011-10-06 | アミラ ファーマシューティカルズ,インク. | Cycloalkane [B] indole antagonist of prostaglandin D2 receptor |
US8071807B2 (en) | 2008-07-03 | 2011-12-06 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
FR2934681B1 (en) | 2008-07-29 | 2011-09-30 | Bastien Karkouche | DEVICE FOR CAPTURING BIOLOGICAL PARTICLES AND USE. |
AU2009279809A1 (en) | 2008-08-04 | 2010-02-11 | Risk Assessment Labs, L.L.C. | Multiplexed diagnostic test for preterm labor |
US8536185B2 (en) | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
US9180114B2 (en) | 2008-11-26 | 2015-11-10 | President And Fellows Of Harvard College | Neurodegenerative diseases and methods of modeling |
WO2010085820A2 (en) | 2009-01-26 | 2010-07-29 | Amira Pharmaceuticals, Inc. | Tricyclic compounds as antagonists of prostaglandin d2 receptors |
WO2010099211A2 (en) | 2009-02-27 | 2010-09-02 | University Of Utah Research Foundation | Compositions and methods for diagnosing and preventing spontaneous preterm birth |
GB0905964D0 (en) | 2009-04-06 | 2009-05-20 | King S College London | Marker |
KR20120047273A (en) | 2009-08-05 | 2012-05-11 | 판미라 파마슈티칼스, 엘엘씨 | Dp2 antagonist and uses thereof |
US20110090048A1 (en) | 2009-09-29 | 2011-04-21 | Li Conan K | Data Transmission Device with User Identification Capability |
AU2010313447A1 (en) | 2009-10-29 | 2012-05-31 | The Trustees Of The University Of Pennsylvania | Method of predicting risk of preterm birth |
WO2011060138A2 (en) | 2009-11-12 | 2011-05-19 | Cervilenz Inc. | Devices and methods for cervix measurement |
EP2504706B1 (en) | 2009-11-25 | 2018-05-23 | Hologic Inc. | Detection of intraamniotic infection |
EP2510356B1 (en) | 2009-12-08 | 2018-10-31 | Cedars-Sinai Medical Center | Diagnostic method to identify women at risk for preterm delivery |
US8874183B2 (en) | 2010-02-18 | 2014-10-28 | The Johns Hopkins University | Preterm labor monitor |
MX2012010035A (en) | 2010-03-16 | 2012-10-01 | Aventis Pharma Inc | Substituted pyrimidines as prostaglandin d2 receptor antagonists. |
BR112012023039A2 (en) | 2010-03-16 | 2016-05-17 | Aventis Pharma Inc | substituted pyrimidine as a prostaglandin d2 receptor antagonist |
CN102791689B (en) | 2010-03-22 | 2014-10-29 | 埃科特莱茵药品有限公司 | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin D2 receptor modulators |
WO2011119757A2 (en) | 2010-03-23 | 2011-09-29 | The Reproductive Research Technologies, Lp | Noninvasive measurement of uterine emg propagation and power spectrum frequency to predict true preterm labor and delivery |
US20110312928A1 (en) | 2010-06-18 | 2011-12-22 | Lipocine Inc. | Progesterone Containing Oral Dosage Forms and Related Methods |
US20110312927A1 (en) | 2010-06-18 | 2011-12-22 | Satish Kumar Nachaegari | Progesterone Containing Oral Dosage Forms and Related Methods |
US20110318308A1 (en) | 2010-06-25 | 2011-12-29 | Winthrop-University Hospital | Lipocalin-type prostaglandin d2 synthase as a biomarker for lung cancer progression and prognosis |
KR101920090B1 (en) | 2010-07-05 | 2018-11-19 | 이도르시아 파마슈티컬스 리미티드 | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
WO2012024034A1 (en) | 2010-07-12 | 2012-02-23 | Therasyn Sensors, Inc. | A device and methods for in vivo monitoring of an individual |
US8765487B2 (en) | 2010-09-01 | 2014-07-01 | Clinical Innovations | Detection of amniotic fluid in vaginal secretions of pregnant women due to premature rupture of fetal membranes |
CN103201628B (en) | 2010-10-01 | 2015-09-16 | 霍罗杰克股份有限公司 | For the immunoassay test strip used in diagnostic system |
EP2670868A4 (en) | 2011-01-31 | 2015-05-06 | Esoterix Genetic Lab Llc | Methods for enriching microparticles or nucleic acids using binding molecules |
US8951996B2 (en) | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
WO2014066568A1 (en) | 2012-10-24 | 2014-05-01 | Winthrop-University Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
-
2013
- 2013-10-24 WO PCT/US2013/066490 patent/WO2014066568A1/en active Application Filing
- 2013-10-24 EP EP13785801.5A patent/EP2912458B1/en not_active Not-in-force
- 2013-10-24 US US14/438,110 patent/US9797903B2/en active Active
- 2013-10-24 EP EP18167167.8A patent/EP3382391A1/en not_active Withdrawn
- 2013-10-24 ES ES13785801.5T patent/ES2690782T3/en active Active
-
2017
- 2017-09-19 US US15/708,582 patent/US10408838B2/en active Active
-
2019
- 2019-07-26 US US16/523,832 patent/US20200018753A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9797903B2 (en) | 2017-10-24 |
EP3382391A1 (en) | 2018-10-03 |
WO2014066568A1 (en) | 2014-05-01 |
EP2912458A1 (en) | 2015-09-02 |
US10408838B2 (en) | 2019-09-10 |
EP2912458B1 (en) | 2018-07-18 |
ES2690782T3 (en) | 2018-11-22 |
US20150285800A1 (en) | 2015-10-08 |
US20180003713A1 (en) | 2018-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10408838B2 (en) | Non-invasive biomarker to identify subject at risk of preterm delivery | |
Khizroeva et al. | Infertility in women with systemic autoimmune diseases | |
Mathur et al. | Distinction between early and late ovarian hyperstimulation syndrome | |
US9518992B2 (en) | Kits for the diagnosis of pre-eclampsia or eclampsia | |
Lisonkova et al. | Atonic postpartum hemorrhage: blood loss, risk factors, and third stage management | |
CN107636466B (en) | Diagnostic assay and treatment of preeclampsia | |
Stefaniak et al. | Pruritus in pregnancy | |
Sanchez et al. | Pulmonary arterial hypertension in women | |
CA2605923C (en) | Use of antagonists of oxytocin and/or vasopressin | |
Naredi et al. | Severe ovarian hyperstimulation syndrome: Can we eliminate it through a multipronged approach? | |
JP2014221783A (en) | Method of preventing premature delivery | |
Wang et al. | Female fertility under the impact of COVID-19 pandemic: a narrative review | |
Essa et al. | Evaluation of prognostic value of Fernandez scoring system on the management of ectopic pregnancy in the emergency room at Suez Canal University Hospitals, Egypt | |
CZ20011524A3 (en) | Use of thiazolidinediones derivatives for preventing uterine contractions in premature labor or lactation | |
BR112019023141A2 (en) | selective asthma treatment methods using il-17 antagonists | |
Carlo et al. | Progestogens in preterm labour prevention: an update | |
Corrà et al. | Case Report: Management of Malignancy-Exacerbated Pemphigus Vulgaris During COVID-19 Pandemic | |
Akol | The Clinical Importance of Retained Placenta Subtypes | |
Camisa | The clinical variants of psoriasis | |
Toll | Pregnancy rhinitis: pathophysiological effects of oestrogen and treatment with oral decongestants | |
Raghavi | A Study on B-HCG in Cervicovaginal Secretions as predictor of preterm delivery | |
Hounslow et al. | Miscarriage | |
Elson | The use of ultrasound and biochemical markers in prediction of pregnancy outcome | |
THYROTOXICOSIS | Hyperthyroid Disorders | |
Mekan et al. | The role of hysteroscopy in diagnosis the pelvic pain syndrome caused by adenomyosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NYU WINTHROP HOSPITAL, NEW YORK Free format text: CHANGE OF NAME;ASSIGNOR:WINTHROP-UNIVERSITY HOSPITAL;REEL/FRAME:049881/0840 Effective date: 20170331 Owner name: WINTHROP-UNIVERSITY HOSPITAL, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RAGOLIA, LOUIS;REEL/FRAME:049878/0246 Effective date: 20131024 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |